These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34258657)

  • 1. Meeting Report: N-Nitrosamine Impurity Control Strategies in the Pharmaceutical and Biotechnology Industries.
    Roberts SW; Lennard A; Mohan G; Bernstein J; Cauchon NS; Cole S; Curristin N; Huynh-Ba K; Kolz CN; Murti C; Tang K
    AAPS J; 2021 Jul; 23(4):94. PubMed ID: 34258657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
    Bharate SS
    J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid.
    Algorri M; Acharya A; Bernstein J; Cauchon NS; Chen XH; Huynh-Ba K; Krantz C; Li T; Li Y; McLamore S; Roberts SW; Schwinke D; Shah R; Schirmer A; Strickland H; Tang K; Watson T
    AAPS Open; 2022; 8(1):19. PubMed ID: 36530577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 7. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 8. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
    Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
    J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
    Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
    Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines and strategy of the International Conference of Harmonization (ICH) and its member states to overcome existing impurity control problems for antibiotics in China.
    Jiang Y; Xia JP; Yang JH; Zhang ZF; Hu CQ; Zhang ZR
    Chin J Nat Med; 2015 Jul; 13(7):498-506. PubMed ID: 26233840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
    Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitrosamine Impurities in Angiotensin Receptor Blockers.
    Shephard EA; Nawarskas JJ
    Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
    Giordani A; Kobel W; Gally HU
    Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies.
    Barber C; Antonucci V; Baumann JC; Brown R; Covey-Crump E; Elder D; Elliott E; Fennell JW; Gallou F; Ide ND; Jordine G; Kallemeyn JM; Lauwers D; Looker AR; Lovelle LE; McLaughlin M; Molzahn R; Ott M; Schils D; Oestrich RS; Stevenson N; Talavera P; Teasdale A; Urquhart MW; Varie DL; Welch D
    Regul Toxicol Pharmacol; 2017 Nov; 90():22-28. PubMed ID: 28822875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessment report of potential impurities in cetirizine dihydrochloride.
    Leistner A; Haerling S; Kreher JD; Becker I; Jung D; Holzgrabe U
    J Pharm Biomed Anal; 2020 Sep; 189():113425. PubMed ID: 32599488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
    Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
    Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract]   [Full Text] [Related]  

  • 20. Adulteration of drugs and foods: compendial approaches to lowering risk.
    Abernethy DR; Sheehan C; Griffiths JC; Williams RL;
    Clin Pharmacol Ther; 2009 Apr; 85(4):444-7. PubMed ID: 18463621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.